Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Bio Rad Labs Inc (BIO)

388 + Investors. Track Smart Money conviction in BIO. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
→ 0
Streak
1Q —
Buyers last Q
55%

Smart Money Signals — BIO

Based on 390 hedge funds · latest filing: 2026 Q1 · updated quarterly

➡️

No change last quarter

last 6Q
The number of hedge funds holding this stock didn't change last quarter. Neither a buying nor selling signal on its own — watch the next quarter for direction.
📊

High ownership — 84% of 3.0Y peak

84% of all-time peak
390 funds currently hold this stock — 84% of the 3.0-year high of 465 funds (reached 2023 Q4). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.
📉

Outflows — 8% fewer funds vs a year ago

fund count last 6Q
33 fewer hedge funds hold BIO compared to a year ago (-8% decline). When institutions consistently reduce their exposure, it's worth exploring the underlying fundamental reasons driving them away.
🟡

Slight buying edge — 55% buying

203 buying165 selling
Last quarter: 203 funds bought or added vs 165 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
➡️

Steady new buyers — ~63 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 57 → 64 → 64 → 63. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
🔒

69% of holders stayed for 2+ years

■ 69% conviction (2yr+) ■ 15% medium ■ 16% new
270 out of 390 hedge funds have held BIO for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
➡️

Steady discovery — ~63 new funds/quarter

74 → 57 → 64 → 64 → 63 new funds/Q
New funds entering each quarter: 57 → 64 → 64 → 63. Consistent flow of new institutional buyers without clear acceleration or slowdown.
🏛️

Veteran-anchored — 73% veterans vs 19% newcomers

■ 73% veterans ■ 7% 1-2yr ■ 19% new
Entry-cohort mix of 394 holders: 289 (73%) are 2+ year veterans, 29 entered 1–2 years ago, and 76 (19%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
✅

Strong quality — 37% AUM from major funds

37% from top-100 AUM funds
56 of 389 holders rank in the top 100 by AUM, accounting for 37% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
2.6
out of 10
Low Exit Risk
Exit risk score 2.6/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — BIO

In 2026 Q1, 203 hedge funds were net buyers of BIO (63 opened a new position, 140 added to an existing one), while 165 reduced or exited (102 trimmed, 63 sold completely) — a 55% buyer ratio, indicating a slight buying edge. 37% of total institutional value in BIO is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: flat (entries and exits balanced). Total institutional holders: 390.

Hedge Fund Ownership: BIO

How many hedge funds hold BIO — quarterly history vs. share price
Quarterly hedge fund ownership of BIO vs. share price

Market Analysis: BIO

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: BIO

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Bio Rad Labs Inc (BIO) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much BIO has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 78d ago
BIO
+4.0%
XLV
+4.3%

BIO outperformed XLV by -0.3% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 33d ago
BIO
+17.1%
XLV
+5.4%

Since the filing became public, BIO outperformed XLV by +11.7% .

Interpretation: The stock has meaningfully outrun its sector. The trade has partially played out; entry is at a premium to the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

32 top-rated funds 3 high-conviction
Consensus
6.6
/ 10
breadth
×
Elite
3.0
/ 10
conviction
Hedge Fund Positioning: BIO
388 + Investors

Track Smart Money conviction in BIO. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 388 390 -0.51%
13F Shares 20M 20M 1.67%
Total Value $5.30B $5.84B -9.16%
New Positions 61 64 -3
Increased Positions 139 109 +30
Closed Positions 63 59 +4
Reduced Positions 101 139 -38
Total Calls 4 4 -
Total Puts 1 1 -
PUT/CALL Ratio 0.25 0.25 Bullish

Statistics: BIO

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

388 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in BIO. Verified SEC 13F-HR filings.

QUARTER:
Top 25 BIO holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 QVIDTVM Management LLC 28.68% 83,732 $23.3M
2 JNE Partners LLP 10.50% 92,100 $25.7M
3 Tikvah Management LLC 8.45% 97,834 $27.3M
4 Hound Partners, LLC 3.41% 97,724 $27.2M
5 Mangrove Partners IM, LLC 2.86% 126,853 $35.4M
6 Ariel Investments, LLC 2.45% 785,961 $219.1M
7 Southeastern Asset Management Inc/Tn/ 2.23% 162,804 $45.4M
8 Almitas Capital LLC 1.91% 30,254 $8.4M
9 First Pacific Advisors, LP 1.59% 407,358 $113.6M
10 Sector Gamma As 1.56% 23,750 $6.6M
11 Nano Cap New Millennium Growth Fund L P 1.17% 4,500 $1.3M
12 Quantedge Capital Pte Ltd 1.06% 6,940 $1.9M
13 First Eagle Investment Management, LLC 0.96% 2,602,772 $725.5M
14 Arnhold LLC 0.88% 42,902 $12.0M
15 Deerfield Management Company, L.P. 0.74% 226,070 $63.0M
16 Hosking Partners LLP 0.69% 69,009 $19.2M
17 Earnest Partners LLC 0.68% 588,731 $164.1M
18 Marathon Asset Management Ltd 0.57% 53,661 $15.0M
19 Alamea Verwaltungs GmbH 0.45% 2,164 $603K
20 Hara Capital LLC 0.42% 2,986 $832K
21 C2C Wealth Management, LLC 0.40% 1,715 $478K
22 Westport Asset Management Inc 0.37% 3,000 $836K
23 Focused Alpha, LLC 0.36% 4,202 $1.2M
24 Mawer Investment Management Ltd. 0.34% 188,784 $52.6M
25 Freestone Grove Partners LP 0.29% 147,605 $41.1M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Bio Rad Labs Inc (BIO)

What does the Smart Money Trend signal show for BIO?

No change last quarter: The number of hedge funds holding this stock didn't change last quarter. Neither a buying nor selling signal on its own — watch the next quarter for direction.

What is the institutional breadth score for BIO?

Slight buying edge — 55% buying: Last quarter: 203 funds bought or added vs 165 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for BIO holders?

Strong quality — 37% AUM from major funds: 56 of 389 holders rank in the top 100 by AUM, accounting for 37% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held BIO?

69% of holders stayed for 2+ years: 270 out of 390 hedge funds have held BIO for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Bio Rad Labs Inc (BIO) following the 2026 Q1 hedge fund 13F filings?

As of today, BIO has moved +17.1% since the 2026 Q1 13F filing date (May 15, 2026), compared to +5.4% for the XLV sector ETF — an outperformance of +11.7%. Since the quarter end (March 31, 2026), BIO has gained +4.0% vs +4.3% for XLV. The stock has meaningfully outrun its sector. The trade has partially played out; entry is at a premium to the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →